News >

Pexidartinib Reduces Tumor Size in Symptomatic Tenosynovial Giant Cell Tumor

Jason Harris
Published: Thursday, Nov 02, 2017

Pexidartinib met its primary endpoint of tumor response as measured by tumor size reduction in patients with symptomatic tenosynovial giant cell tumor (TGCT) where surgical resection is contraindicated, according to results from the phase III ENLIVEN trial.

The most common pexidartinib-related all-grade adverse events (AEs) were changes in hair color (74%), fatigue (65%), nausea (39%), dysgeusia (26%), and periorbital edema (26%). The most frequent grade ≥3 AEs were hyponatremia (9%), elevated aspartate aminotransferase or alanine aminotransferase level or both (9%), fatigue (4%), diarrhea (4%), anemia (4%), and neutropenia 4%.
Tap WD, Wainberg ZA, Anthony SP, et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015;373:428-437.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication